#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Sonny Hsiao Email
CEO/CSO, President and Co-Founder . Acepodia
How to contact Sonny Hsiao
Join and see Sonny's contact info for free!Current Roles
Employees:
57Revenue:
$8.8MAbout
Acepodia is using its proprietary bioconjugation technology to develop the next wave of off-the-shelf cell therapies for cancer. Our ACC™ platform simply and cost effectively links antibodies directly to immune cells, enhancing their tumor-killing ability without the need for genetic manipulation. Relative to other cellular immunotherapy approaches, ACC™ requires no genetic engineering of immune cells, and has a substantially improved dose-titration capability. Broadly tested with various existing antibodies, ACC™ is capable of arming effector cells with available antibodies. Acepodia production cell line, ACE-NK, is capable of allogeneic usage due to its lack of TCR (T-cell receptor) property. ACE-NK cells are super-charged with ACC™ to overcome suppressive tumor microenvironment. The lead program ACE1702 (anti-HER2 conjugated NK cells) has been validated both in vitro and in vivo, presenting promising treatment possibilities in a variety of cancer types. ACE1702 is planned to enter Phase 1 in 2019.Acepodia Address
1600 Harbor Bay ParkwaySan Mateo, CA
United States